Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Caberdost Cabergoline Tablets IP 0.5 mg
Caberdost Cabergoline Tablets IP 0.5 mg contain Cabergoline, a potent dopamine receptor agonist known for its efficacy in reducing high prolactin levels. It is commonly prescribed for the treatment of disorders associated with hyperprolactinemia.
Uses of Caberdost Cabergoline Tablets IP 0.5 mg
Hyperprolactinemia: Effectively treats elevated prolactin levels, which can cause various reproductive and metabolic issues.
Menstrual Disorders: Helps regulate menstrual cycles in women experiencing irregular periods due to high prolactin levels.
Infertility Treatment: Assists in restoring fertility in both men and women by normalizing prolactin levels.
Pituitary Adenomas: Used in the management of prolactin-secreting pituitary tumors.
Benefits of Caberdost Cabergoline Tablets IP 0.5 mg
Effective Prolactin Reduction: Rapidly decreases prolactin levels, helping to restore hormonal balance.
Long-Lasting Effects: Has a long half-life, allowing for less frequent dosing and better compliance.
Improved Reproductive Health: Alleviates symptoms such as infertility, galactorrhea, and sexual dysfunction.
Well-Tolerated: Generally well-tolerated with a favorable side effect profile compared to other prolactin-lowering medications.
Mechanism of Action of Caberdost Cabergoline Tablets IP 0.5 mg
Dopamine Receptor Agonism: Cabergoline stimulates dopamine receptors (D2 receptors) in the pituitary gland, inhibiting the secretion of prolactin.
Reduced Prolactin Secretion: By activating dopamine receptors, it decreases the release of prolactin from the pituitary gland, lowering blood levels of the hormone.
Tumor Shrinkage: In cases of prolactin-secreting tumors, Cabergoline can reduce tumor size and improve associated symptoms.
Restored Hormonal Balance: Helps restore the balance of other hormones that are affected by elevated prolactin levels, improving overall health and well-being.